RxDoctor Payments Data

Bina Joseph, MD

Allergy & Immunology · Lafayette, LANPI 1346232212

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $542, 3.9 times the $140 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in LA, where the typical reported total is $3,029.

$792in general payments, 2019–2025

Across 33 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$189
  • AstraZeneca$87
  • Novartis$84
  • CSL Behring$81
  • Amgen$57
  • Regeneron Healthcare Solutions, Inc.$48
  • plus $246 from 9 others

What the payments were for

  • Food & beverage$75896%
  • Education$344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$792 in reported general payments places this provider in the 25th percentile of 62 allergy & immunology providers in Louisiana.

See all allergy & immunology providers in Louisiana

Medicare billing

Part B allowed, 2024
$15,987
Medicare patients
51
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab14$36,415
Arnuity ElliptaFluticasone Furoate26$7,434
Epinephrine13$2,616
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,709
Albuterol Sulfate HfaAlbuterol Sulfate46$1,220
Wixela InhubFluticasone Propion/Salmeterol21$1,213
Azelastine Hcl32$921
Montelukast Sodium78$424
Fluticasone Propionate29$337
Hydroxyzine Hcl26$280
Levocetirizine Dihydrochloride23$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$19$7,43426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 62 allergy & immunology providers in Louisiana.

Other allergy & immunology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →